Details of the Drug

General Information of Drug (ID: DMBDAZV)

Drug Name

Amlodipine

Synonyms

Amlocard; Amlodipino; Amlodipinum; Amlodis; Amlopres; Amlor; Coroval; Intervask; Lipinox; AMLODIPINE BASE; Amlodipine Free Base; Amlodipino [Spanish]; Amlodipinum [Latin]; Racemic Amlodipine; Amlodipine (INN); Amlodipine [INN:BAN]; Dailyvasc (TN); Istin (TN); Norvasc (TN); Perivasc (TN); UK-4834011; R,S)-Amlodipine; 2-[(2-Aminoethoxy)methyl]-4-(2-chlorophenyl); 3,5-Pyridinedicarboxylic acid, 2-((2-aminoethoxy)methyl)-4-(2-chlorophenyl)-1,4-dihydro-6-methyl-, 3-ethyl 5-methyl ester; 3,5-Pyridinedicarboxylic acid, 2-[(2-aminoethoxy)methyl]-4-(2-chlorophenyl)-1,4-dihydro-6-methyl-, 3-ethyl 5-methyl ester; 3-Ethyl-5-methyl (+-)-2-(2-aminoethoxymethyl)-4-(o-chlorophenyl)-1,4-dihydro-6-methyl-3,5-pyridinedicarboxylate; 3-Ethyl-5-methyl (+/-)-2-[(2-aminoethoxy)methyl]-4-(o-chlorophenyl)-1,4-dihydro-6-methyl-3,5-pyridinedicarboxylate; 3-Ethyl-5-methyl (-)-2-((2-aminoethoxy)methyl)-4-(2-chlorphenyl)-1,4-dihydro-6-methyl-3,5-pyridindicarboxylat; 3-Ethyl-5-methyl (-)-2-((2-aminoethoxymethyl)-4-(o-chlorophenyl)-1,4-dihydro-6-methyl-3,5-pyridinedicarboxylate; 3-O-ethyl 5-O-methyl 2-(2-aminoethoxymethyl)-4-(2-chlorophenyl)-6-methyl-1,4-dihydropyridine-3,5-dicarboxylate; 3-ethyl 5-methyl 2-[(2-aminoethoxy)methyl]-4-(2-chlorophenyl)-6-methyl-1,4-dihydropyridine-3,5-dicarboxylate; 3-ethyl 5-methyl 2-{[(2-aminoethyl)oxy]methyl}-4-(2-chlorophenyl)-6-methyl-1,4-dihydropyridine-3,5-dicarboxylate

Indication

Disease Entry	ICD 11	Status	REF
Angina pectoris	BA40	Approved	[1]
Chronic heart failure	BD1Z	Approved	[1]
Hypertension	BA00-BA04	Approved	[2]
Malignant essential hypertension	BA00	Approved	[1]
Stroke	8B20	Investigative	[1]
------------------------------------------------------------------------------------

Therapeutic Class

Antihypertensive Agents

Drug Type

Small molecular drug

Structure

3D MOL

2D MOL

#Ro5 Violations (Lipinski): 0

Molecular Weight (mw)

408.9

Logarithm of the Partition Coefficient (xlogp)

Rotatable Bond Count (rotbonds)

Hydrogen Bond Donor Count (hbonddonor)

Hydrogen Bond Acceptor Count (hbondacc)

ADMET Property

Absorption Cmax: The maximum plasma concentration (Cmax) of drug is 8.8-45.8 mcg/L []
Absorption Tmax: The time to maximum plasma concentration (Tmax) is 3.5 h []
BDDCS Class: Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 1: high solubility and high permeability [3]
Bioavailability: The bioavailability of drug is 30% []
Clearance: The total body clearance of drug is 7 +/- 1.3 mL/min/kg [4]
Elimination: 10% of drug is excreted from urine in the unchanged form [3]
Half-life: The concentration or amount of drug in body reduced by one-half in 30C50 hours []
Metabolism: The drug is metabolized via the hepatic [5]
MRTD: The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 0.3494 micromolar/kg/day [6]
Unbound Fraction: The unbound fraction of drug in plasma is 0.005% [7]
Vd: The volume of distribution (Vd) of drug is 21 L/kg [4]

Adverse Drug Reaction (ADR)

ADR Term	Variation	Related DOT	DOT ID	REF
Cardiovascular disorder	rs5065	NPPA	OTMQNTNX	[8]
-----------

Chemical Identifiers

Formula: C20H25ClN2O5
IUPAC Name: 3-O-ethyl 5-O-methyl 2-(2-aminoethoxymethyl)-4-(2-chlorophenyl)-6-methyl-1,4-dihydropyridine-3,5-dicarboxylate
Canonical SMILES: CCOC(=O)C1=C(NC(=C(C1C2=CC=CC=C2Cl)C(=O)OC)C)COCCN
InChI: InChI=1S/C20H25ClN2O5/c1-4-28-20(25)18-15(11-27-10-9-22)23-12(2)16(19(24)26-3)17(18)13-7-5-6-8-14(13)21/h5-8,17,23H,4,9-11,22H2,1-3H3
InChIKey: HTIQEAQVCYTUBX-UHFFFAOYSA-N

Cross-matching ID

PubChem CID: 2162
ChEBI ID: CHEBI:2668
CAS Number: 88150-42-9
DrugBank ID: DB00381
TTD ID: D08JIV
VARIDT ID: DR00563
INTEDE ID: DR0099
ACDINA ID: D00033

Combinatorial Drugs (CBD)

Click to Jump to the Detailed CBD Information of This Drug

Repurposed Drugs (RPD)

Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Voltage-gated calcium channel alpha-2/delta-1 (CACNA2D1)	TTFK1JQ	CA2D1_HUMAN	Blocker	[9]

------------------------------------------------------------------------------------

Drug-Metabolizing Enzyme (DME)

DME Name	DME ID	UniProt ID	MOA	REF
Cytochrome P450 3A4 (CYP3A4)_{Main DME}	DE4LYSA	CP3A4_HUMAN	Substrate	[10]

------------------------------------------------------------------------------------

Drug Off-Target (DOT)

DOT Name	DOT ID	UniProt ID	Interaction	REF
Adiponectin (ADIPOQ)	OTNX23LE	ADIPO_HUMAN	Gene/Protein Processing	[11]
Aromatase (CYP19A1)	OTZ6XF74	CP19A_HUMAN	Gene/Protein Processing	[12]
Cyclin-dependent kinase 2 (CDK2)	OTB5DYYZ	CDK2_HUMAN	Gene/Protein Processing	[13]
Cyclin-dependent kinase inhibitor 1 (CDKN1A)	OTQWHCZE	CDN1A_HUMAN	Gene/Protein Processing	[13]
Cytochrome P450 1A1 (CYP1A1)	OTE4EFH8	CP1A1_HUMAN	Gene/Protein Processing	[14]
Cytochrome P450 1B1 (CYP1B1)	OTYXFLSD	CP1B1_HUMAN	Gene/Protein Processing	[15]
Cytochrome P450 2B6 (CYP2B6)	OTOYO4S7	CP2B6_HUMAN	Gene/Protein Processing	[14]
Cytochrome P450 2J2 (CYP2J2)	OTJBTEH8	CP2J2_HUMAN	Gene/Protein Processing	[16]
Cytochrome P450 3A5 (CYP3A5)	OTSXFBXB	CP3A5_HUMAN	Drug Response	[17]
Endothelin-1 (EDN1)	OTZCACEG	EDN1_HUMAN	Gene/Protein Processing	[18]

------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA)

MIA Detail

Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease

Angina pectoris

ICD Disease Classification

BA40

Molecule Name	Molecule Type	Gene Name	p-value	Fold-Change	Z-score
Voltage-gated calcium channel alpha-2/delta-1 (CACNA2D1)	DTT	CACNA2D1	9.36E-01	-0.03	-0.13
Voltage-gated calcium channel alpha-2/delta-1 (CACNA2D1)	DTT	CACNA2D1	2.81E-05	-0.15	-0.68
Cytochrome P450 3A4 (CYP3A4)	DME	CYP3A4	2.13E-01	4.03E-02	2.50E-01
Cytochrome P450 3A4 (CYP3A4)	DME	CYP3A4	8.21E-02	8.17E-02	4.35E-01

Molecular Expression Atlas (MEA)

MEA Detail

Jump to Detail Molecular Expression Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Same Disease as Amlodipine

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Disease	REF
Acebutolol	DM0TI4U	Moderate	Increased risk of cardiac depression by the combination of Amlodipine and Acebutolol.	Hypertension [BA00-BA04]	[19]
Bisoprolol	DM3UZ95	Moderate	Increased risk of cardiac depression by the combination of Amlodipine and Bisoprolol.	Hypertension [BA00-BA04]	[19]
Penbutolol	DM4ES8F	Moderate	Increased risk of cardiac depression by the combination of Amlodipine and Penbutolol.	Hypertension [BA00-BA04]	[19]
Verapamil	DMA7PEW	Moderate	Decreased metabolism of Amlodipine caused by Verapamil mediated inhibition of CYP450 enzyme.	Hypertension [BA00-BA04]	[20]
Pindolol	DMD2NV7	Moderate	Increased risk of cardiac depression by the combination of Amlodipine and Pindolol.	Hypertension [BA00-BA04]	[19]
Labetalol	DMK8U72	Moderate	Increased risk of cardiac depression by the combination of Amlodipine and Labetalol.	Hypertension [BA00-BA04]	[19]
-----------


⏷ Show the Full List of 6 DDI Information of This Drug

Coadministration of a Drug Treating the Disease Different from Amlodipine (Comorbidity)

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Comorbidity	REF
Ivosidenib	DM8S6T7	Moderate	Increased metabolism of Amlodipine caused by Ivosidenib mediated induction of CYP450 enzyme.	Acute myeloid leukaemia [2A60]	[21]
Midostaurin	DMI6E0R	Moderate	Decreased metabolism of Amlodipine caused by Midostaurin mediated inhibition of CYP450 enzyme.	Acute myeloid leukaemia [2A60]	[22]
Arn-509	DMT81LZ	Major	Increased metabolism of Amlodipine caused by Arn-509 mediated induction of CYP450 enzyme.	Acute myeloid leukaemia [2A60]	[23]
Gilteritinib	DMTI0ZO	Moderate	Decreased metabolism of Amlodipine caused by Gilteritinib mediated inhibition of CYP450 enzyme.	Acute myeloid leukaemia [2A60]	[24]
Magnesium Sulfate	DMVEK07	Moderate	Additive hypotensive effects by the combination of Amlodipine and Magnesium Sulfate.	Acute pain [MG31]	[25]
Emapalumab	DMZG5WL	Moderate	Altered metabolism of Amlodipine due to Emapalumab alters the formation of CYP450 enzymes.	Adaptive immunity immunodeficiency [4A01]	[24]
Mitotane	DMU1GX0	Major	Increased metabolism of Amlodipine caused by Mitotane mediated induction of CYP450 enzyme.	Adrenal cancer [2D11]	[23]
Siltuximab	DMGEATB	Moderate	Altered metabolism of Amlodipine due to Siltuximab alters the formation of CYP450 enzymes.	Anemia [3A00-3A9Z]	[24]
Methylphenobarbital	DMDSWAG	Moderate	Increased metabolism of Amlodipine caused by Methylphenobarbital mediated induction of CYP450 enzyme.	Anxiety disorder [6B00-6B0Z]	[26]
Promazine	DMZAL7W	Moderate	Additive hypotensive effects by the combination of Amlodipine and Promazine.	Appearance/behaviour symptom [MB23]	[27]
Cilostazol	DMZMSCT	Moderate	Decreased metabolism of Amlodipine caused by Cilostazol mediated inhibition of CYP450 enzyme.	Arterial occlusive disease [BD40]	[28]
Voriconazole	DMAOL2S	Moderate	Decreased metabolism of Amlodipine caused by Voriconazole mediated inhibition of CYP450 enzyme.	Aspergillosis [1F20]	[29]
Posaconazole	DMUL5EW	Moderate	Decreased metabolism of Amlodipine caused by Posaconazole mediated inhibition of CYP450 enzyme.	Aspergillosis [1F20]	[29]
Zileuton	DMVRIC2	Minor	Decreased metabolism of Amlodipine caused by Zileuton mediated inhibition of CYP450 enzyme.	Asthma [CA23]	[30]
Ciprofloxacin XR	DM2NLS9	Moderate	Decreased metabolism of Amlodipine caused by Ciprofloxacin XR mediated inhibition of CYP450 enzyme.	Bacterial infection [1A00-1C4Z]	[20]
Dalfopristin	DM4LTKV	Moderate	Decreased metabolism of Amlodipine caused by Dalfopristin mediated inhibition of CYP450 enzyme.	Bacterial infection [1A00-1C4Z]	[20]
Clarithromycin	DM4M1SG	Moderate	Decreased metabolism of Amlodipine caused by Clarithromycin mediated inhibition of CYP450 enzyme.	Bacterial infection [1A00-1C4Z]	[20]
Chloramphenicol	DMFXEWT	Moderate	Decreased metabolism of Amlodipine caused by Chloramphenicol mediated inhibition of CYP450 enzyme.	Bacterial infection [1A00-1C4Z]	[20]
Linezolid	DMGFPU2	Moderate	Additive hypotensive effects by the combination of Amlodipine and Linezolid.	Bacterial infection [1A00-1C4Z]	[31]
Telithromycin	DMZ4P3A	Moderate	Decreased metabolism of Amlodipine caused by Telithromycin mediated inhibition of CYP450 enzyme.	Bacterial infection [1A00-1C4Z]	[20]
Cariprazine	DMJYDVK	Moderate	Additive hypotensive effects by the combination of Amlodipine and Cariprazine.	Bipolar disorder [6A60]	[27]
Erdafitinib	DMI782S	Moderate	Increased metabolism of Amlodipine caused by Erdafitinib mediated induction of CYP450 enzyme.	Bladder cancer [2C94]	[32]
Lapatinib	DM3BH1Y	Moderate	Decreased metabolism of Amlodipine caused by Lapatinib mediated inhibition of CYP450 enzyme.	Breast cancer [2C60-2C6Y]	[33]
Tucatinib	DMBESUA	Moderate	Decreased metabolism of Amlodipine caused by Tucatinib mediated inhibition of CYP450 enzyme.	Breast cancer [2C60-2C6Y]	[20]
Bosutinib	DMTI8YE	Moderate	Decreased metabolism of Amlodipine caused by Bosutinib mediated inhibition of CYP450 enzyme.	Breast cancer [2C60-2C6Y]	[24]
Sotalol	DML60TN	Moderate	Increased risk of cardiac depression by the combination of Amlodipine and Sotalol.	Cardiac arrhythmia [BC9Z]	[19]
Atorvastatin	DMF28YC	Moderate	Decreased metabolism of Amlodipine caused by Atorvastatin mediated inhibition of CYP450 enzyme.	Cardiovascular disease [BA00-BE2Z]	[34]
Secobarbital	DM14RF5	Moderate	Increased metabolism of Amlodipine caused by Secobarbital mediated induction of CYP450 enzyme.	Chronic insomnia [7A00]	[26]
PF-04449913	DMSB068	Moderate	Decreased metabolism of Amlodipine caused by PF-04449913 mediated inhibition of CYP450 enzyme.	Chronic myelomonocytic leukaemia [2A40]	[35]
Thiopental	DMGP8AX	Moderate	Increased metabolism of Amlodipine caused by Thiopental mediated induction of CYP450 enzyme.	Corneal disease [9A76-9A78]	[26]
Mifepristone	DMGZQEF	Moderate	Decreased metabolism of Amlodipine caused by Mifepristone mediated inhibition of CYP450 enzyme.	Cushing syndrome [5A70]	[36]
Pasireotide	DMHM7JS	Moderate	Increased risk of bradycardia by the combination of Amlodipine and Pasireotide.	Cushing syndrome [5A70]	[20]
Osilodrostat	DMIJC9X	Moderate	Decreased metabolism of Amlodipine caused by Osilodrostat mediated inhibition of CYP450 enzyme.	Cushing syndrome [5A70]	[24]
Lumacaftor	DMCLWDJ	Major	Increased metabolism of Amlodipine caused by Lumacaftor mediated induction of CYP450 enzyme.	Cystic fibrosis [CA25]	[23]
Ivacaftor	DMZC1HS	Moderate	Decreased metabolism of Amlodipine caused by Ivacaftor mediated inhibition of CYP450 enzyme.	Cystic fibrosis [CA25]	[37]
MK-8228	DMOB58Q	Moderate	Decreased metabolism of Amlodipine caused by MK-8228 mediated inhibition of CYP450 enzyme.	Cytomegaloviral disease [1D82]	[20]
Aprepitant	DM053KT	Moderate	Decreased metabolism of Amlodipine caused by Aprepitant mediated inhibition of CYP450 enzyme.	Depression [6A70-6A7Z]	[20]
Fluoxetine	DM3PD2C	Moderate	Decreased metabolism of Amlodipine caused by Fluoxetine mediated inhibition of CYP450 enzyme.	Depression [6A70-6A7Z]	[20]
Nefazodone	DM4ZS8M	Moderate	Decreased metabolism of Amlodipine caused by Nefazodone mediated inhibition of CYP450 enzyme.	Depression [6A70-6A7Z]	[20]
Selegiline	DM6034S	Moderate	Additive hypotensive effects by the combination of Amlodipine and Selegiline.	Depression [6A70-6A7Z]	[31]
Isocarboxazid	DMAF1NB	Moderate	Additive hypotensive effects by the combination of Amlodipine and Isocarboxazid.	Depression [6A70-6A7Z]	[31]
Tranylcypromine	DMGB5RE	Moderate	Additive hypotensive effects by the combination of Amlodipine and Tranylcypromine.	Depression [6A70-6A7Z]	[31]
OPC-34712	DMHG57U	Moderate	Additive hypotensive effects by the combination of Amlodipine and OPC-34712.	Depression [6A70-6A7Z]	[27]
Phenelzine	DMHIDUE	Moderate	Additive hypotensive effects by the combination of Amlodipine and Phenelzine.	Depression [6A70-6A7Z]	[31]
Polatuzumab vedotin	DMF6Y0L	Moderate	Decreased metabolism of Amlodipine caused by Polatuzumab vedotin mediated inhibition of CYP450 enzyme.	Diffuse large B-cell lymphoma [2A81]	[38]
Primidone	DM0WX6I	Major	Increased metabolism of Amlodipine caused by Primidone mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[23]
Oxcarbazepine	DM5PU6O	Moderate	Increased metabolism of Amlodipine caused by Oxcarbazepine mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[39]
Mephenytoin	DM5UGDK	Moderate	Increased metabolism of Amlodipine caused by Mephenytoin mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[40]
Cenobamate	DM8KLU9	Moderate	Increased metabolism of Amlodipine caused by Cenobamate mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[41]
Stiripentol	DMMSDOY	Moderate	Decreased metabolism of Amlodipine caused by Stiripentol mediated inhibition of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[20]
Fosphenytoin	DMOX3LB	Major	Increased metabolism of Amlodipine caused by Fosphenytoin mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[23]
Rufinamide	DMWE60C	Moderate	Increased metabolism of Amlodipine caused by Rufinamide mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[24]
Ethotoin	DMXWOCP	Moderate	Increased metabolism of Amlodipine caused by Ethotoin mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[40]
Phenobarbital	DMXZOCG	Major	Increased metabolism of Amlodipine caused by Phenobarbital mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[23]
Carbamazepine	DMZOLBI	Major	Increased metabolism of Amlodipine caused by Carbamazepine mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[42]
Nadolol	DMW6GVL	Moderate	Increased risk of cardiac depression by the combination of Amlodipine and Nadolol.	Essential hypertension [BA00]	[19]
Dantrolene	DM1D8XY	Moderate	Increased risk of hyperkalemia by the combination of Amlodipine and Dantrolene.	Fever [MG26]	[36]
Tazemetostat	DMWP1BH	Moderate	Increased metabolism of Amlodipine caused by Tazemetostat mediated induction of CYP450 enzyme.	Follicular lymphoma [2A80]	[43]
Darifenacin	DMWXLYZ	Moderate	Decreased metabolism of Amlodipine caused by Darifenacin mediated inhibition of CYP450 enzyme.	Functional bladder disorder [GC50]	[44]
Miconazole	DMPMYE8	Moderate	Decreased metabolism of Amlodipine caused by Miconazole mediated inhibition of CYP450 enzyme.	Fungal infection [1F29-1F2F]	[29]
Ketoconazole	DMPZI3Q	Moderate	Decreased metabolism of Amlodipine caused by Ketoconazole mediated inhibition of CYP450 enzyme.	Fungal infection [1F29-1F2F]	[29]
Ripretinib	DM958QB	Moderate	Decreased metabolism of Amlodipine caused by Ripretinib mediated inhibition of CYP450 enzyme.	Gastrointestinal stromal tumour [2B5B]	[36]
Avapritinib	DMK2GZX	Moderate	Decreased metabolism of Amlodipine caused by Avapritinib mediated inhibition of CYP450 enzyme.	Gastrointestinal stromal tumour [2B5B]	[24]
Carteolol	DMFMDOB	Moderate	Increased risk of cardiac depression by the combination of Amlodipine and Carteolol.	Glaucoma [9C61]	[19]
Metipranolol	DMJMVKI	Moderate	Increased risk of cardiac depression by the combination of Amlodipine and Metipranolol.	Glaucoma [9C61]	[45]
Levobetaxolol	DMSREPX	Moderate	Increased risk of cardiac depression by the combination of Amlodipine and Levobetaxolol.	Glaucoma [9C61]	[45]
Levobunolol	DMTNFCQ	Moderate	Increased risk of cardiac depression by the combination of Amlodipine and Levobunolol.	Glaucoma [9C61]	[45]
Ergotamine	DMKR3C5	Moderate	Decreased metabolism of Amlodipine caused by Ergotamine mediated inhibition of CYP450 enzyme.	Headache [8A80-8A84]	[46]
Carvedilol	DMHTEAO	Moderate	Increased risk of cardiac depression by the combination of Amlodipine and Carvedilol.	Heart failure [BD10-BD1Z]	[19]
Boceprevir	DMBSHMF	Moderate	Decreased metabolism of Amlodipine caused by Boceprevir mediated inhibition of CYP450 enzyme.	Hepatitis virus infection [1E50-1E51]	[47]
Simeprevir	DMLUA9D	Moderate	Decreased metabolism of Amlodipine caused by Simeprevir mediated inhibition of CYP450 enzyme.	Hepatitis virus infection [1E50-1E51]	[48]
Telaprevir	DMMRV29	Moderate	Decreased metabolism of Amlodipine caused by Telaprevir mediated inhibition of CYP450 enzyme.	Hepatitis virus infection [1E50-1E51]	[47]
Rifampin	DMA8J1G	Major	Increased metabolism of Amlodipine caused by Rifampin mediated induction of CYP450 enzyme.	HIV-infected patients with tuberculosis [1B10-1B14]	[23]
Rifapentine	DMCHV4I	Major	Increased metabolism of Amlodipine caused by Rifapentine mediated induction of CYP450 enzyme.	HIV-infected patients with tuberculosis [1B10-1B14]	[23]
Procarbazine	DMIK367	Moderate	Additive hypotensive effects by the combination of Amlodipine and Procarbazine.	Hodgkin lymphoma [2B30]	[31]
MK-1439	DM215WE	Minor	Decreased metabolism of Amlodipine caused by MK-1439 mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[49]
Delavirdine	DM3NF5G	Moderate	Decreased metabolism of Amlodipine caused by Delavirdine mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[50]
Fosamprenavir	DM4W9B3	Moderate	Decreased metabolism of Amlodipine caused by Fosamprenavir mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[20]
Cobicistat	DM6L4H2	Moderate	Decreased metabolism of Amlodipine caused by Cobicistat mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[20]
Efavirenz	DMC0GSJ	Moderate	Increased metabolism of Amlodipine caused by Efavirenz mediated induction of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[51]
Saquinavir	DMG814N	Moderate	Decreased metabolism of Amlodipine caused by Saquinavir mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[20]
Etravirine	DMGV8QU	Moderate	Increased metabolism of Amlodipine caused by Etravirine mediated induction of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[52]
Rilpivirine	DMJ0QOW	Moderate	Decreased metabolism of Amlodipine caused by Rilpivirine mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[36]
Amprenavir	DMLMXE0	Moderate	Decreased metabolism of Amlodipine caused by Amprenavir mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[20]
Darunavir	DMN3GCH	Moderate	Decreased metabolism of Amlodipine caused by Darunavir mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[20]
Atazanavir	DMSYRBX	Moderate	Decreased metabolism of Amlodipine caused by Atazanavir mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[53]
Ritonavir	DMU764S	Moderate	Decreased metabolism of Amlodipine caused by Ritonavir mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[20]
Simvastatin	DM30SGU	Major	Decreased metabolism of Amlodipine caused by Simvastatin mediated inhibition of CYP450 enzyme.	Hyper-lipoproteinaemia [5C80]	[54]
BMS-201038	DMQTAGO	Moderate	Decreased metabolism of Amlodipine caused by BMS-201038 mediated inhibition of CYP450 enzyme.	Hyper-lipoproteinaemia [5C80]	[55]
Cerivastatin	DMXCM7H	Moderate	Decreased metabolism of Amlodipine caused by Cerivastatin mediated inhibition of CYP450 enzyme.	Hyper-lipoproteinaemia [5C80]	[34]
Conivaptan	DM1V329	Moderate	Decreased metabolism of Amlodipine caused by Conivaptan mediated inhibition of CYP450 enzyme.	Hypo-osmolality/hyponatraemia [5C72]	[56]
Lesinurad	DMUR64T	Moderate	Increased metabolism of Amlodipine caused by Lesinurad mediated induction of CYP450 enzyme.	Inborn purine/pyrimidine/nucleotide metabolism error [5C55]	[57]
Berotralstat	DMWA2DZ	Moderate	Decreased metabolism of Amlodipine caused by Berotralstat mediated inhibition of CYP450 enzyme.	Innate/adaptive immunodeficiency [4A00]	[20]
Amobarbital	DM0GQ8N	Moderate	Increased metabolism of Amlodipine caused by Amobarbital mediated induction of CYP450 enzyme.	Insomnia [7A00-7A0Z]	[26]
Propiomazine	DMKY8V1	Moderate	Additive hypotensive effects by the combination of Amlodipine and Propiomazine.	Insomnia [7A00-7A0Z]	[27]
ITI-007	DMUQ1DO	Moderate	Decreased metabolism of Amlodipine caused by ITI-007 mediated inhibition of CYP450 enzyme.	Insomnia [7A00-7A0Z]	[58]
Pemigatinib	DM819JF	Moderate	Decreased metabolism of Amlodipine caused by Pemigatinib mediated inhibition of CYP450 enzyme.	Liver cancer [2C12]	[24]
Porfimer Sodium	DM7ZWNY	Moderate	Increased risk of photosensitivity reactions by the combination of Amlodipine and Porfimer Sodium.	Lung cancer [2C25]	[59]
Lurbinectedin	DMEFRTZ	Moderate	Decreased metabolism of Amlodipine caused by Lurbinectedin mediated inhibition of CYP450 enzyme.	Lung cancer [2C25]	[60]
PF-06463922	DMKM7EW	Moderate	Decreased metabolism of Amlodipine caused by PF-06463922 mediated inhibition of CYP450 enzyme.	Lung cancer [2C25]	[61]
Pralsetinib	DMWU0I2	Moderate	Decreased metabolism of Amlodipine caused by Pralsetinib mediated inhibition of CYP450 enzyme.	Lung cancer [2C25]	[62]
Selpercatinib	DMZR15V	Moderate	Decreased metabolism of Amlodipine caused by Selpercatinib mediated inhibition of CYP450 enzyme.	Lung cancer [2C25]	[24]
Idelalisib	DM602WT	Moderate	Decreased metabolism of Amlodipine caused by Idelalisib mediated inhibition of CYP450 enzyme.	Mature B-cell leukaemia [2A82]	[20]
IPI-145	DMWA24P	Moderate	Decreased metabolism of Amlodipine caused by IPI-145 mediated inhibition of CYP450 enzyme.	Mature B-cell leukaemia [2A82]	[20]
Acalabrutinib	DM7GCVW	Moderate	Decreased metabolism of Amlodipine caused by Acalabrutinib mediated inhibition of CYP450 enzyme.	Mature B-cell lymphoma [2A85]	[63]
Selumetinib	DMC7W6R	Moderate	Decreased metabolism of Amlodipine caused by Selumetinib mediated inhibition of CYP450 enzyme.	Melanoma [2C30]	[64]
LGX818	DMNQXV8	Moderate	Increased metabolism of Amlodipine caused by LGX818 mediated induction of CYP450 enzyme.	Melanoma [2C30]	[65]
Dabrafenib	DMX6OE3	Moderate	Increased metabolism of Amlodipine caused by Dabrafenib mediated induction of CYP450 enzyme.	Melanoma [2C30]	[24]
Ubrogepant	DM749I3	Moderate	Decreased metabolism of Amlodipine caused by Ubrogepant mediated inhibition of CYP450 enzyme.	Migraine [8A80]	[66]
Propranolol	DM79NTF	Moderate	Increased risk of cardiac depression by the combination of Amlodipine and Propranolol.	Migraine [8A80]	[19]
Exjade	DMHPRWG	Moderate	Decreased metabolism of Amlodipine caused by Exjade mediated inhibition of CYP450 enzyme.	Mineral absorption/transport disorder [5C64]	[67]
Thalidomide	DM70BU5	Moderate	Increased risk of ventricular arrhythmias by the combination of Amlodipine and Thalidomide.	Multiple myeloma [2A83]	[36]
Siponimod	DM2R86O	Major	Increased risk of atrioventricular block by the combination of Amlodipine and Siponimod.	Multiple sclerosis [8A40]	[36]
Fingolimod	DM5JVAN	Moderate	Increased risk of atrioventricular block by the combination of Amlodipine and Fingolimod.	Multiple sclerosis [8A40]	[68]
Ozanimod	DMT6AM2	Moderate	Increased risk of atrioventricular block by the combination of Amlodipine and Ozanimod.	Multiple sclerosis [8A40]	[69]
Rifabutin	DM1YBHK	Major	Increased metabolism of Amlodipine caused by Rifabutin mediated induction of CYP450 enzyme.	Mycobacterium infection [1B10-1B21]	[23]
Fedratinib	DM4ZBK6	Moderate	Decreased metabolism of Amlodipine caused by Fedratinib mediated inhibition of CYP450 enzyme.	Myeloproliferative neoplasm [2A20]	[20]
Nilotinib	DM7HXWT	Moderate	Decreased metabolism of Amlodipine caused by Nilotinib mediated inhibition of CYP450 enzyme.	Myeloproliferative neoplasm [2A20]	[70]
Imatinib	DM7RJXL	Moderate	Decreased metabolism of Amlodipine caused by Imatinib mediated inhibition of CYP450 enzyme.	Myeloproliferative neoplasm [2A20]	[20]
Modafinil	DMYILBE	Minor	Increased metabolism of Amlodipine caused by Modafinil mediated induction of CYP450 enzyme.	Narcolepsy [7A20]	[71]
Prochlorperazine	DM53SRA	Moderate	Additive hypotensive effects by the combination of Amlodipine and Prochlorperazine.	Nausea/vomiting [MD90]	[27]
Promethazine	DM6I5GR	Moderate	Additive hypotensive effects by the combination of Amlodipine and Promethazine.	Nausea/vomiting [MD90]	[27]
Netupitant	DMEKAYI	Moderate	Decreased metabolism of Amlodipine caused by Netupitant mediated inhibition of CYP450 enzyme.	Nausea/vomiting [MD90]	[20]
Entrectinib	DMMPTLH	Moderate	Decreased metabolism of Amlodipine caused by Entrectinib mediated inhibition of CYP450 enzyme.	Non-small cell lung cancer [2C25]	[72]
Rucaparib	DM9PVX8	Moderate	Decreased metabolism of Amlodipine caused by Rucaparib mediated inhibition of CYP450 enzyme.	Ovarian cancer [2C73]	[73]
Safinamide	DM0YWJC	Moderate	Additive hypotensive effects by the combination of Amlodipine and Safinamide.	Parkinsonism [8A00]	[31]
Rasagiline	DM3WKQ4	Moderate	Additive hypotensive effects by the combination of Amlodipine and Rasagiline.	Parkinsonism [8A00]	[31]
Abametapir	DM2RX0I	Moderate	Decreased metabolism of Amlodipine caused by Abametapir mediated inhibition of CYP450 enzyme.	Pediculosis [1G00]	[74]
Lefamulin	DME6G97	Moderate	Decreased metabolism of Amlodipine caused by Lefamulin mediated inhibition of CYP450 enzyme.	Pneumonia [CA40]	[75]
Ergonovine	DM0VEC1	Moderate	Decreased metabolism of Amlodipine caused by Ergonovine mediated inhibition of CYP450 enzyme.	Postpartum haemorrhage [JA43]	[76]
Lonafarnib	DMGM2Z6	Major	Decreased metabolism of Amlodipine caused by Lonafarnib mediated inhibition of CYP450 enzyme.	Premature ageing appearance [LD2B]	[77]
Enzalutamide	DMGL19D	Major	Increased metabolism of Amlodipine caused by Enzalutamide mediated induction of CYP450 enzyme.	Prostate cancer [2C82]	[23]
Darolutamide	DMV7YFT	Minor	Decreased metabolism of Amlodipine caused by Darolutamide mediated inhibition of CYP450 enzyme.	Prostate cancer [2C82]	[78]
Ustekinumab	DMHTYK3	Moderate	Altered metabolism of Amlodipine due to Ustekinumab alters the formation of CYP450 enzymes.	Psoriasis [EA90]	[24]
Ixekizumab	DMXW92T	Moderate	Altered metabolism of Amlodipine due to Ixekizumab alters the formation of CYP450 enzymes.	Psoriasis [EA90]	[24]
Levomepromazine	DMIKFEL	Moderate	Additive hypotensive effects by the combination of Amlodipine and Levomepromazine.	Psychotic disorder [6A20-6A25]	[27]
Triflupromazine	DMKFQJP	Moderate	Additive hypotensive effects by the combination of Amlodipine and Triflupromazine.	Psychotic disorder [6A20-6A25]	[27]
Bosentan	DMIOGBU	Moderate	Increased metabolism of Amlodipine caused by Bosentan mediated induction of CYP450 enzyme.	Pulmonary hypertension [BB01]	[79]
Everolimus	DM8X2EH	Moderate	Decreased metabolism of Amlodipine caused by Everolimus mediated inhibition of CYP450 enzyme.	Renal cell carcinoma [2C90]	[36]
Axitinib	DMGVH6N	Moderate	Decreased metabolism of Amlodipine caused by Axitinib mediated inhibition of CYP450 enzyme.	Renal cell carcinoma [2C90]	[24]
Temsirolimus	DMS104F	Moderate	Decreased metabolism of Amlodipine caused by Temsirolimus mediated inhibition of CYP450 enzyme.	Renal cell carcinoma [2C90]	[36]
Tocilizumab	DM7J6OR	Moderate	Altered metabolism of Amlodipine due to Tocilizumab alters the formation of CYP450 enzymes.	Rheumatoid arthritis [FA20]	[24]
Canakinumab	DM8HLO5	Moderate	Altered metabolism of Amlodipine due to Canakinumab alters the formation of CYP450 enzymes.	Rheumatoid arthritis [FA20]	[24]
Rilonacept	DMGLUQS	Moderate	Altered metabolism of Amlodipine due to Rilonacept alters the formation of CYP450 enzymes.	Rheumatoid arthritis [FA20]	[24]
Golimumab	DMHZV7X	Moderate	Altered metabolism of Amlodipine due to Golimumab alters the formation of CYP450 enzymes.	Rheumatoid arthritis [FA20]	[24]
Sarilumab	DMOGNXY	Moderate	Altered metabolism of Amlodipine due to Sarilumab alters the formation of CYP450 enzymes.	Rheumatoid arthritis [FA20]	[24]
Quetiapine	DM1N62C	Moderate	Additive hypotensive effects by the combination of Amlodipine and Quetiapine.	Schizophrenia [6A20]	[27]
Mesoridazine	DM2ZGAN	Moderate	Additive hypotensive effects by the combination of Amlodipine and Mesoridazine.	Schizophrenia [6A20]	[27]
Thioridazine	DM35M8J	Moderate	Additive hypotensive effects by the combination of Amlodipine and Thioridazine.	Schizophrenia [6A20]	[27]
Aripiprazole	DM3NUMH	Moderate	Additive hypotensive effects by the combination of Amlodipine and Aripiprazole.	Schizophrenia [6A20]	[27]
Iloperidone	DM6AUFY	Moderate	Additive hypotensive effects by the combination of Amlodipine and Iloperidone.	Schizophrenia [6A20]	[27]
Paliperidone	DM7NPJS	Moderate	Additive hypotensive effects by the combination of Amlodipine and Paliperidone.	Schizophrenia [6A20]	[27]
Loxapine	DM8AI9U	Moderate	Additive hypotensive effects by the combination of Amlodipine and Loxapine.	Schizophrenia [6A20]	[27]
Haloperidol	DM96SE0	Moderate	Additive hypotensive effects by the combination of Amlodipine and Haloperidol.	Schizophrenia [6A20]	[27]
Perphenazine	DMA4MRX	Moderate	Additive hypotensive effects by the combination of Amlodipine and Perphenazine.	Schizophrenia [6A20]	[27]
Molindone	DMAH70G	Moderate	Additive hypotensive effects by the combination of Amlodipine and Molindone.	Schizophrenia [6A20]	[27]
Chlorpromazine	DMBGZI3	Moderate	Additive hypotensive effects by the combination of Amlodipine and Chlorpromazine.	Schizophrenia [6A20]	[27]
Thiothixene	DMDINC4	Moderate	Additive hypotensive effects by the combination of Amlodipine and Thiothixene.	Schizophrenia [6A20]	[27]
Trifluoperazine	DMKBYWI	Moderate	Additive hypotensive effects by the combination of Amlodipine and Trifluoperazine.	Schizophrenia [6A20]	[27]
Risperidone	DMN6DXL	Moderate	Additive hypotensive effects by the combination of Amlodipine and Risperidone.	Schizophrenia [6A20]	[27]
Amisulpride	DMSJVAM	Moderate	Additive hypotensive effects by the combination of Amlodipine and Amisulpride.	Schizophrenia [6A20]	[27]
Asenapine	DMSQZE2	Moderate	Additive hypotensive effects by the combination of Amlodipine and Asenapine.	Schizophrenia [6A20]	[27]
Voxelotor	DMCS6M5	Moderate	Decreased metabolism of Amlodipine caused by Voxelotor mediated inhibition of CYP450 enzyme.	Sickle-cell disorder [3A51]	[20]
Telotristat ethyl	DMDIYFZ	Moderate	Increased metabolism of Amlodipine caused by Telotristat ethyl mediated induction of CYP450 enzyme.	Small intestine developmental anomaly [DA90]	[24]
Larotrectinib	DM26CQR	Moderate	Decreased metabolism of Amlodipine caused by Larotrectinib mediated inhibition of CYP450 enzyme.	Solid tumour/cancer [2A00-2F9Z]	[36]
Armodafinil	DMGB035	Minor	Increased metabolism of Amlodipine caused by Armodafinil mediated induction of CYP450 enzyme.	Solid tumour/cancer [2A00-2F9Z]	[71]
LEE011	DMMX75K	Moderate	Decreased metabolism of Amlodipine caused by LEE011 mediated inhibition of CYP450 enzyme.	Solid tumour/cancer [2A00-2F9Z]	[20]
Fostamatinib	DM6AUHV	Moderate	Decreased metabolism of Amlodipine caused by Fostamatinib mediated inhibition of CYP450 enzyme.	Thrombocytopenia [3B64]	[80]
Apixaban	DM89JLN	Moderate	Decreased metabolism of Amlodipine caused by Apixaban mediated inhibition of CYP450 enzyme.	Thrombosis [DB61-GB90]	[24]
Sirolimus	DMGW1ID	Moderate	Decreased metabolism of Amlodipine caused by Sirolimus mediated inhibition of CYP450 enzyme.	Transplant rejection [NE84]	[36]
Methdilazine	DMAUHQX	Moderate	Additive hypotensive effects by the combination of Amlodipine and Methdilazine.	Vasomotor/allergic rhinitis [CA08]	[27]
Trimeprazine	DMEMV9D	Moderate	Additive hypotensive effects by the combination of Amlodipine and Trimeprazine.	Vasomotor/allergic rhinitis [CA08]	[81]
-----------


⏷ Show the Full List of 172 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG

DIG Name	DIG ID	PubChem CID	Functional Classification
Butylated hydroxytoluene	E00336	31404	Antioxidant
FD&C blue no. 2	E00446	2723854	Colorant
Mannitol	E00103	6251	Diluent; Flavoring agent; Lyophilization aid; Plasticizing agent; Tonicity agent
Sodium lauryl sulfate	E00464	3423265	Emulsifying agent; Modified-release agent; Penetration agent; Solubilizing agent; Surfactant; lubricant
Stearic acid	E00079	5281	Emulsifying agent; Solubilizing agent; Viscosity-controlling agent; lubricant
Brushite	E00392	104805	Diluent
Calcium hydrogenphosphate	E00294	24441	Diluent
Calcium phosphate	E00298	24456	Anticaking agent; Buffering agent; Desiccant; Diluent
Crospovidone	E00626	Not Available	Disintegrant
Eisenoxyd	E00585	56841934	Colorant
Ferrosoferric oxide	E00231	14789	Colorant
Gelatin	E00630	Not Available	Other agent
Lactose monohydrate	E00393	104938	Binding agent; Diluent; Dry powder inhaler carrier; Lyophilization aid
Magnesium stearate	E00208	11177	lubricant
Polysorbate 80	E00665	Not Available	Dispersing agent; Emollient; Emulsifying agent; Plasticizing agent; Solubilizing agent; Surfactant; Suspending agent
Silicon dioxide	E00670	Not Available	Anticaking agent; Opacifying agent; Viscosity-controlling agent
Talc	E00520	16211421	Anticaking agent; Diluent; Glidant; lubricant
Titanium dioxide	E00322	26042	Coating agent; Colorant; Opacifying agent
Hydrophobic colloidal silica	E00285	24261	Anticaking agent; Emulsion stabilizing agent; Glidant; Suspending agent; Viscosity-controlling agent
Trihydroxystearin	E00317	25100	Emollient; Emulsifying agent; Solvent; Surfactant; Viscosity-controlling agent
Cellulose microcrystalline	E00698	Not Available	Adsorbent; Suspending agent; Diluent
--------------------


⏷ Show the Full List of 21 Pharmaceutical Excipients of This Drug

Pharmaceutical Formulation

Formulation Name	Drug Dosage	Dosage Form	Route
Amlodipine 10 mg tablet	10 mg	Oral Tablet	Oral
Amlodipine 2.5 mg tablet	2.5 mg	Oral Tablet	Oral
Amlodipine 5 mg tablet	5 mg	Oral Tablet	Oral
Amlodipine Besylate eq 2.5mg base capsule	eq 2.5mg base	Capsule	Oral
Amlodipine Besylate eq 10mg base tablet	eq 10mg base	Tablet	Oral
Amlodipine Besylate eq 5mg base tablet	eq 5mg base	Tablet	Oral

Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1	Amlodipine FDA Label
2	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6981).
3	BDDCS applied to over 900 drugs
4	Meredith PA, Elliott HL: Clinical pharmacokinetics of amlodipine. Clin Pharmacokinet. 1992 Jan;22(1):22-31. doi: 10.2165/00003088-199222010-00003.
5	Shore N, Zurth C, Fricke R, Gieschen H, Graudenz K, Koskinen M, Ploeger B, Moss J, Prien O, Borghesi G, Petrenciuc O, Tammela TL, Kuss I, Verholen F, Smith MR, Fizazi K: Evaluation of Clinically Relevant Drug-Drug Interactions and Population Pharmacokinetics of Darolutamide in Patients with Nonmetastatic Castration-Resistant Prostate Cancer: Results of Pre-Specified and Post Hoc Analyses of the Phase III ARAMIS Trial. Target Oncol. 2019 Oct;14(5):527-539. doi: 10.1007/s11523-019-00674-0.
6	Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
7	Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
8	Pharmacogenetic association of the NPPA T2238C genetic variant with cardiovascular disease outcomes in patients with hypertension. JAMA. 2008 Jan 23;299(3):296-307. doi: 10.1001/jama.299.3.296.
9	A first drug combination for the treatment of arterial hypertension with a calcium channel antagonist (amlodipine besylate) and an angiotensin receptor blocker (valsartan): Exforge. Rev Med Liege. 2007 Nov;62(11):688-94.
10	Amlodipine metabolism in human liver microsomes and roles of CYP3A4/5 in the dihydropyridine dehydrogenation. Drug Metab Dispos. 2014 Feb;42(2):245-9.
11	Amlodipine improves endothelial function and metabolic parameters in patients with hypertension. Int J Cardiol. 2009 Mar 20;133(1):23-31. doi: 10.1016/j.ijcard.2007.11.058. Epub 2008 Jan 15.
12	Cell-based high-throughput screening for aromatase inhibitors in the Tox21 10K library. Toxicol Sci. 2015 Oct;147(2):446-57.
13	G1 cell cycle arrest by amlodipine, a dihydropyridine Ca2+ channel blocker, in human epidermoid carcinoma A431 cells. Biochem Pharmacol. 2007 Apr 1;73(7):943-53. doi: 10.1016/j.bcp.2006.12.011. Epub 2006 Dec 14.
14	Inhibition of human cytochrome P450 enzymes by 1,4-dihydropyridine calcium antagonists: prediction of in vivo drug-drug interactions. Eur J Clin Pharmacol. 2000 Feb-Mar;55(11-12):843-52.
15	Association of CYP1A1 and CYP1B1 inhibition in in vitro assays with drug-induced liver injury. J Toxicol Sci. 2021;46(4):167-176. doi: 10.2131/jts.46.167.
16	Inhibitory effects of antihypertensive drugs on human cytochrome P450 2J2 activity: Potent inhibition by azelnidipine and manidipine. Chem Biol Interact. 2019 Jun 1;306:1-9.
17	Comparing antihypertensive effect and plasma ciclosporin concentration between amlodipine and valsartan regimens in hypertensive renal transplant patients receiving ciclosporin therapy. Am J Cardiovasc Drugs. 2011 Dec 1;11(6):401-9. doi: 10.2165/11593800-000000000-00000.
18	Role of transforming growth factor-beta1 in the progression of chronic allograft nephropathy. Nephrol Dial Transplant. 2001;16 Suppl 1:114-6. doi: 10.1093/ndt/16.suppl_1.114.
19	Anastassiades CJ "Nifedipine and beta-blocker drugs." Br Med J 281 (1980): 1251-2. [PMID: 6107167]
20	Canadian Pharmacists Association.
21	Product Information. Tibsovo (ivosidenib). Agios Pharmaceuticals, Cambridge, MA.
22	Dutreix C, Munarini F, Lorenzo S, Roesel J, Wang Y "Investigation into CYP3A4-mediated drug-drug interactions on midostaurin in healthy volunteers." Cancer Chemother Pharmacol 72 (2013): 1223-34. [PMID: 24085261]
23	Product Information. Mycobutin (rifabutin). Pharmacia and Upjohn, Kalamazoo, MI.
24	Cerner Multum, Inc. "UK Summary of Product Characteristics.".
25	Benami M, Giladi Y, Shalev E "The combination of magnesium sulphate and nifedipine - a cause of neuromuscular blockade." Br J Obstet Gynaecol 101 (1994): 262-3. [PMID: 8193107]
26	Hamann SR, Blouin RA, Chang SL, et al "Effects of hemodynamic changes on the elimination kinetics of verapamil and nifedipine." J Pharmacol Exp Ther 231 (1984): 301-5. [PMID: 6491984]
27	Aronowitz JS, Chakos MH, Safferman AZ, Lieberman JA "Syncope associated with the combination of clozapine and enalapril." J Clin Psychopharmacol 14 (1994): 429-30. [PMID: 7884028]
28	Hedaya MA, El-Afify DR, El-Maghraby GM "The effect of ciprofloxacin and clarithromycin on sildenafil oral bioavailability in human volunteers." Biopharm Drug Dispos 27 (2006): 103-10. [PMID: 16372380]
29	Heinig R, Adelmann HG, Ahr G "The effect of ketoconazole on the pharmacokinetics, pharmacodynamics and safety of nisoldipine." Eur J Clin Pharmacol 55 (1999): 57-60. [PMID: 10206086]
30	Product Information. Zylo Filmtab (zileuton). Abbott Pharmaceutical, Abbott Park, IL.
31	Ban TA "Drug interactions with psychoactive drugs." Dis Nerv Syst 36 (1975): 164-6. [PMID: 1116424]
32	Product Information. Balversa (erdafitinib). Janssen Products, LP, Horsham, PA.
33	Product Information. Tykerb (lapatinib). Novartis Pharmaceuticals, East Hanover, NJ.
34	Agbin NE, Brater DC, Hall SD "Interaction of diltiazem with lovastatin and pravastatin." Clin Pharmacol Ther 61 (1997): 201. [PMID: 9797793]
35	Product Information. Daurismo (glasdegib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
36	Cerner Multum, Inc. "Australian Product Information.".
37	Product Information. Kalydeco (ivacaftor). Vertex Pharmaceuticals, Cambridge, MA.
38	Product Information. Polivy (polatuzumab vedotin). Genentech, South San Francisco, CA.
39	Product Information. Trileptal (oxcarbazepine) Novartis Pharmaceuticals, East Hanover, NJ.
40	Ahmad S "Nifedipine-phenytoin interaction." J Am Coll Cardiol 3 (1984): 1582. [PMID: 6425385]
41	Product Information. Xcopri (cenobamate). SK Life Science, Inc., Paramus, NJ.
42	Bahls FH, Ozuna J, Ritchie DE "Interactions between calcium channel blockers and the anticonvulsants carbamazepine and phenytoin." Neurology 41 (1991): 740-2. [PMID: 2027492]
43	Product Information. Tazverik (tazemetostat). Epizyme, Inc, Cambridge, MA.
44	Product Information. Enablex (darifenacin). Novartis Pharmaceuticals, East Hanover, NJ.
45	Henry M, Kay MM, Viccellio P "Cardiogenic shock associated with calcium-channel and beta blockers: reversal with intravenous calcium chloride." Am J Emerg Med 3 (1985): 334-6. [PMID: 2860911]
46	Ausband SC, Goodman PE "An unusual case of clarithromycin associated ergotism." J Emerg Med 4 (2001): 411-3. [PMID: 11728770]
47	Product Information. Incivek (telaprevir). Vertex Pharmaceuticals, Cambridge, MA.
48	Product Information. Olysio (simeprevir). Janssen Pharmaceuticals, Titusville, NJ.
49	Product Information. Pifeltro (doravirine). Merck & Company Inc, Whitehouse Station, NJ.
50	Product Information. Rescriptor (delavirdine). Pharmacia and Upjohn, Kalamazoo, MI.
51	Product Information. Sustiva (efavirenz). DuPont Pharmaceuticals, Wilmington, DE.
52	Product Information. Intelence (etravirine). Ortho Biotech Inc, Bridgewater, NJ.
53	Product Information. Reyataz (atazanavir). Bristol-Myers Squibb, Princeton, NJ.
54	Product Information. Zocor (simvastatin). Merck & Co, Inc, West Point, PA.
55	Product Information. Juxtapid (lomitapide). Aegerion Pharmaceuticals Inc, Cambridge, MA.
56	Product Information. Vaprisol (conivaptan). Cumberland Pharmaceuticals Inc, Nashville, TN.
57	Product Information. Zurampic (lesinurad). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
58	Product Information. Caplyta (lumateperone). Intra-Cellular Therapies, Inc., New York, NY.
59	Blakely KM, Drucker AM, Rosen CF "Drug-induced photosensitivity-an update: Culprit drugs, prevention and management." Drug Saf 42 (2019): 827-47. [PMID: 30888626]
60	Product Information. Zepzelca (lurbinectedin). Jazz Pharmaceuticals, Palo Alto, CA.
61	Product Information. Lorbrena (lorlatinib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
62	Product Information. Gavreto (pralsetinib). Blueprint Medicines Corporation, Cambridge, MA.
63	Product Information. Calquence (acalabrutinib). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
64	Product Information. Koselugo (selumetinib). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
65	Product Information. Braftovi (encorafenib). Array BioPharma Inc., Boulder, CO.
66	Product Information. Ubrelvy (ubrogepant). Allergan Inc, Irvine, CA.
67	Product Information. Exjade (deferasirox). Novartis Pharmaceuticals, East Hanover, NJ.
68	Product Information. Gilenya (fingolimod). Novartis Pharmaceuticals, East Hanover, NJ.
69	Product Information. Zeposia (ozanimod). Celgene Corporation, Summit, NJ.
70	Product Information. Tasigna (nilotinib). Novartis Pharmaceuticals, East Hanover, NJ.
71	Doherty MM, Charman WN "The mucosa of the small intestine: how clinically relevant as an organ of drug metabolism?" Clin Pharmacokinet 41 (2002): 235-53. [PMID: 11978143]
72	Product Information. Rozlytrek (entrectinib). Genentech, South San Francisco, CA.
73	EMA. European Medicines Agency. European Union "EMA - List of medicines under additional monitoring.".
74	Product Information. Xeglyze (abametapir topical). Dr. Reddy's Laboratories Inc, Upper Saddle River, NJ.
75	Product Information. Xenleta (lefamulin). Nabriva Therapeutics US, Inc., King of Prussia, PA.
76	Francis H, Tyndall A, Webb J "Severe vascular spasm due to erythromycin-ergotamine interaction." Clin Rheumatol 3 (1984): 243-6. [PMID: 6236021]
77	Product Information. Zokinvy (lonafarnib). Eiger BioPharmaceuticals, Palo Alto, CA.
78	Product Information. Nubeqa (darolutamide). Bayer HealthCare Pharmaceuticals Inc., Whippany, NJ.
79	Product Information. Tracleer (bosentan). Acetelion Pharmaceuticals US, Inc, South San Francisco, CA.
80	Product Information. Tavalisse (fostamatinib). Rigel Pharmaceuticals, South San Francisco, CA.
81	Product Information. Clozaril (clozapine). Novartis Pharmaceuticals, East Hanover, NJ.